U.S. biotechnology firm Gilead Sciences has announced that it will donate 1.5 million doses of its experimental anti-CCP-virus drug, remdesivir, for compassionate use, expanded access, and clinical trials.
“Over the course of the past week, Gilead has been working in consultation with regulatory authorities to establish additional expanded access programs for remdesivir, our investigational medicine for COVID-19,” O'Day said.
“The programs enable hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at a time. These are patients who cannot take part in clinical trials and where the word ‘emergency’ is all too real for them, their families, and the healthcare providers advocating on their behalf.”
The company has also “set an ambitious goal” of boosting its supply of remdesivir to more than 500,000 treatment courses by October and more than 1 million treatment courses by the end of this year. Production time has also been accelerated and, as a result, the end-to-end manufacturing timeline has been reduced from approximately one year to around six months, according to the statement.
“Our efforts to increase supply continue with a strong sense of urgency. There is a long way to go and a lot of work to be done, but I’m pleased that, despite the challenges, we have been able to get supply levels to where they are today in a very short space of time—through the resourcefulness of our teams, creative approaches, and collaboration,” O'Day said.
Remdesivir, which hasn’t been given regulatory approval, was initially developed by Gilead as a potential treatment for the Ebola virus. O'Day noted that the safety and efficacy of the drug aren’t yet known, and that, “while we feel the greatest sense of urgency in our work with remdesivir, we must take the responsible, ethical approach of determining whether it is indeed a safe, effective treatment.”
Multiple clinical trials for the drug are underway, with thousands of patients with CCP virus participating across the world, the CEO said.
Doctors in the United States are currently prescribing hydroxychloroquine, as are France and Bahrain, while India has recommended it for health care workers. However, health officials have warned the public to remain cautious until larger clinical trials validate smaller studies.